GlaxoSmithKline posts Q2FY22 consolidated PAT at Rs. 204.24 Cr

GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021

Sun Pharma's Winlevi available in the US

It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years

Laurus Labs PAT at Rs 201.90 cr. in Q2FY21

Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021

Zydus Wellness PAT at Rs. 21.47 cr. in Q2FY22

Zydus Wellness Limited has reported consolidated financial results for the period ended September 30, 2021

Mandaviya launches the sixth edition of National Formulary of India (NFI)

The NFI is published to promote the rational use of medicines in the country.

3M Health Care and Thermo Fisher to increase efficiency in therapeutic manufacturing

Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers

Transforming Healthcare Through AI

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.

Ocugen submits IND application with U.S. FDA for Covaxin phase 3 trial

The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population

Novartis receives priority review by U.S. FDA and filing acceptance by EMA for Kymriah

Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications